Medindia LOGIN REGISTER
Medindia
Advertisement

Max Neeman International Continues to Expand in Response to Increased Client Demand for Medical Writing Services

Tuesday, July 13, 2010 Drug News
Advertisement
Indian CRO Prepared for Accelerated Growth of the Medical Writing Market

RESEARCH TRIANGLE PARK, N.C., July 13 /PRNewswire/ -- Max Neeman International, India's premier CRO, has expanded its team of medical writers in response to the growing demand for medical writing services.  The team consists of highly qualified medical writers with scientific or medical educations and clinical experience.  The expansion now allows for medical writers to be assigned to a project who have the specific therapeutic and document expertise it requires.  The newly expanded team works closely with the biostatistics, quality assurance, regulatory and clinical operations groups to better serve the client.
Advertisement

The medical writing team at Max Neeman has generated clinical study reports, protocols across various therapeutic areas including oncology, cardiology, endocrinology, and vascular diseases as well as investigator brochures and manuscripts.
Advertisement

India has become a major destination for medical writing services because of the stream of medical scientists entering the job market each year, including on average 3 million graduates and 700,000 post graduates.  The focus on medical education propels India's cost advantage and competitiveness in the medical writing space.

The medical writing market has doubled in size during the past five years, increasing from an estimated US$ 345 million in 2003 to US$ 694 million in 2008 and is expected to grow further at an accelerated pace.  Max Neeman can provide cost savings of 35-50% for conduct of clinical trials and services in India compared to the United States.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to [email protected] or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.

SOURCE Max Neeman International

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close